12:10 PM - 1:10 PM
12:10 pm - 12:15 PM
Combination EBRT and Brachytherapy Boost is Associated with Improved Overall Survival Relative to Definitive Brachytherapy in Unfavorable Intermediate-Risk Prostate Cancer
Neal Andruska, MD
12:15 PM - 12:20PM
Patient-Reported Urinary Symptoms after Prostate Brachytherapy - Is There a Relationship with Bladder Neck Dose?
Sean Koerner, MD
12:20 PM - 12:25 PM
Interobserver Variability of Target and OAR Delineation in MRI-Based Prostate Brachytherapy across Two Anatomical Pulse Sequences
Jeremiah Sanders, PhD
12:25 PM - 12:30 PM
High Dose Rate Monotherapy in Localized Prostate Cancer: Efficacy Results and Prostate-Specific Antigen Kinetics
Miren Gaztañaga, MD
12:30 pm - 12:35 PM
Permanent Interstitial LDR-Brachytherapy for Prostate Cancer Implementing Prostatic Artery Embolization
Hathal Haddad, MD
12:35 PM - 12:40 PM
After ASCENDE-RT: Outcomes of Androgen Deprivation, External Beam Radiation and LDR Brachytherapy Boost for High-Tier Intermediate and High Risk Prostate Cancer
Jack Zheng
12:40 PM - 12:45 PM
Does the Sequence of High-Dose Rate Brachytherapy Boost and IMRT for Prostate Cancer Impact Early Disease and Toxicity Outcomes? Results from a Single Institution Analysis
Amit Roy, MD
12:45 PM - 12:59 PM
Feasibility and Efficacy of Bladder Neck Urethral Sparing Technique in Prostate Brachytherapy
Ryan Smith, MD
12:50 PM - 12:55 PM
Are the Risk Groups Used for External Beam Treatment of Prostate Cancer Appropriate for LDR Brachytherapy Treatment?
Howard Thames, PhD
12:45 PM - 12:50 PM
Effect of Short-Term Corticosteroid Usage on Acute Urinary Toxicity Following Cs-131 Prostate Brachytherapy
Andrew Keller, MD
12:55 PM - 1:00 PM
Low Dose Rate Brachytherapy before or after Transurethral Resection of the Prostate
Vishal Dhere, MD
1:00 PM - 1:05 PM
Dosimetric Predictors of Toxicity and Quality of Life Following Single Fraction High Dose-Rate Prostate Brachytherapy
Mark Corkum, MD